The cost-effectiveness of male HPV vaccination in the United States

Vaccine

Volumn 29, Issue 46, 2011, Pages 8443-8450

  Chesson, Harrell W ^a   Ekwueme, Donatus U ^b   Saraiya, Mona ^b   Dunne, Eileen F ^a   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Cost effectiveness analysis; Disease transmission models; Human papillomavirus; Vaccines

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANUS CANCER; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PAPILLOMATOSIS; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SEX DIFFERENCE; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VAGINA CANCER; VIRUS TRANSMISSION; VULVA CANCER; WART VIRUS;

ADOLESCENT; ADULT; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INCIDENCE; MALE; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY OF LIFE; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 80053987404     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.096     Document Type: Article

References (38)

1. Institute of Medicine Vaccines for the 21st century: a tool for decisionmaking 2000, National Academy of Sciences, Washington, DC.
2. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604-615.
3. Sanders G.D., Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003, 9:37-48.
4. Kulasingam S.L., Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290:781-789.
5. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10:1915-1923.
6. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13:28-41.
7. Chesson H.W., Ekwueme D.U., Saraiya M., Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008, 14:244-251.
8. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
9. Kim J.J., Goldie S.J. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:b3884.
10. Elbasha E.H., Dasbach E. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28:6858-6867.
11. Brisson M., Van de Velde N., Boily M.C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351.
12. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
13. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
14. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271-278.
15. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943.
16. Munoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
17. Palefsky J., Guiliano A. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. European Research Organization on Genital Infection and Neoplasia (EUROGIN Conference 2008) 2008.
18. Guiliano A., Palefsky J. The efficacy of quadrivalent HPV (types 6/11/16/19) vaccine in reducing the incidence of HPV-related genital disease in young men. European Research Organization on Genital Infection and Neoplasia (EUROGIN Conference 2008) 2008.
19. Stokley S., Dorell C., Yankey D. National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2008. MMWR Morb Mortal Wkly Rep 2009, 58:997-1001.
20. Dorell C., Stokley S., Yankey D., Cohn A., Markowitz L. National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2009. MMWR Morb Mortal Wkly Rep 2010, 59(August (32)):1018-1023.
21. Markowitz L. HPV vaccine session background. Meeting of the Advisory Committee on Immunization Practices 2011, http://www.cdc.gov/vaccines/recs/acip/meetings.htm.
22. Grosse S.D. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008, 8:165-178.
23. Bach P.B. Gardasil: from bench, to bedside, to blunder. Lancet 2010, 375(9719):963-964.
24. Zimet G.D. Understanding and overcoming barriers to human papillomavirus vaccine acceptance. Curr Opin Obstet Gynecol 2006, 18:s23-s28.
25. Dempsey A.F., Davis M.M. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care 2006, 12:S484-S491.
26. Garnett G.P., Kim J.J., French K., Goldie S.J. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, (Suppl. 3):S178-S186.
27. Van de Velde N., Brisson M., Boily M.C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28(33):5473-5484.
28. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
29. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
30. Insinga R.P., Glass A.G., Rush B.B. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004, 191:105-113.
31. Kulasingam S., Connelly L., Conway E., Hocking J.S., Myers E., Regan D.G., et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007, 4:165-175.
32. Insinga R.P., Glass A.G., Myers E.R., Rush B.B. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007, 27:414-422.
33. Hoy T., Singhal P.K., Willey V.J., Insinga R.P. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009, 25:2343-2351.
34. Hu D., Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198:500-507.
35. Woodhall S.C., Jit M., Cai C., Ramsey T., Zia S., Crouch S., et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009, 36:515-521.
36. Insinga R.P., Ye X., Singhal P.K., Carides G.W. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan. Gynecol Oncol 2008, 111:188-196.
37. Armstrong L.R., Preston E.J., Reichert M., Phillips D.L., Nisenbaum R., Todd N.W., et al. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000, 31:107-109.
38. Chesson H.W., Forhan S.E., Gottlieb S.L., Markowitz L.E. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 2008, 26:4513-4518.